Dr. Siddiqi, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, offers impressions of the Transcend-NHL data investigating the use of CAR-T cell therapy in chronic lymphocytic leukemia (CLL) patients presented at ASH 2019

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Brent Wood (University of Washington, Seattle, WA) discusses the phase III Children's Oncology Group (COG) study AALL0434, which evaluated a standard 4-drug induction followed by response-based risk stratification, as determined by measured levels of minimal residual disease (MRD), in patients with T-lymphocytic leukemia. Intermediate and high-risk patients were randomized to receive or not receive additional nelarabine chemotherapy and all patients except those who were low-risk received additional radiation therapy.

Predicting response of patients with chronic lymphocytic leukemia to chimeric antigen receptor (CAR) T cell therapy nominated by the University of Pennsylvania, represented by Dr. Joseph A. Fraietta, Assistant Professor of Microbiology and Director, Tumor Immunotherapy Laboratory, Center for Cellular Immunotherapies. A common reason for failure of the immune system to eliminate leukemia is that it does not recognize and kill cancer cells. It is now possible to use gene engineering to introduce synthetic molecules, such as chimeric antigen receptors (CARs) into T cells allowing them to recognize and destroy a patient’s own cancer.

Erika Florendo, BS, MS, of The Mount Sinai Hospital, New York, NY, discusses the role of the nurse in the use of CAR T-cell therapy for the treatment of multiple myeloma, the challenges faced by these nurses and how these can be overcome. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Rod Humerickhouse, MD, PhD, asset strategy leader at AbbVie discusses the results from his company's phase 3 MURANO trial investigating venetoclax/rituximab combination for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) at the 60th ASH Annual Meeting in San Diego. Among the results, a reduced risk in disease progression and 87.9% overall survival in treated patients were highlighted.

In the MURANO clinical trial, 78% of patients who completed the two-year treatment course of VenR without disease progression (N=114) also demonstrated minimal residual disease (MRD)-negativity in peripheral blood. MRD-negativity was a secondary endpoint assessed at the end of combination therapy (nine-month assessment). MRD-negativity (also known as undetectable MRD) is an objective measure defined as the presence of less than one CLL cell in 10,000 white blood cells remaining in the blood or bone marrow following treatment. Earlier prospective clinical trials in CLL patients have provided evidence that achieving MRD-negativity is associated with improved clinical outcomes.

Leukemia is a group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells. These blood cells are not fully developed and are called blasts or leukemia cells. In 2015, leukemia was present in 2.3 million people worldwide and caused 353,500 deaths.

In this video, we have explained everything you need to know about leukemia.

0:00 What is leukemia?
0:39 Leukemia symptoms (Symptoms of leukemia)
1:13 Leukemia causes (Causes of leukemia)
1:57 Leukemia classification (Classification of leukemia)
2:11 Acute leukemia
2:26 Chronic leukemia
2:44 Lymphocytic leukemia & myelogenous leukemia
3:12 Leukemia types (Types of leukemia)
3:56 Risk factors of leukemia
4:15 Leukemia diagnosis (Diagnosis of leukemia)
5:13 Leukemia treatment (Treatment of leukemia)

Hope you will like the video, Please support us by subscribing to our channel. Also follow us on our Instagram and facebook.

#bloodcancer #bloodcancerawareness #leukemiaawareness #leukemia #leukemiatreatment